ZielBio is an early-stage biotechnology company that identifies novel high value disease targets.
ZielBio has raised $7.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.
ZielBio's investors include Partners Innovation Fund, Morningside, Mass General Brigham Ventures.
ZielBio is headquartered in Charlottesville, United States.
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets.
ZielBio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ZielBio — Funding & Investors." VCBacked, September 27, 2022, https://www.vcbacked.co/company/zielbio. Accessed August 16, 2026.
VCBacked. (2022). ZielBio — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/zielbio
{{cite web |title=ZielBio — Funding & Investors |url=https://www.vcbacked.co/company/zielbio |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated